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Abstract The purpose of this study was to investigate the
incidence, clinical presentation, and prognosis of
Actinotignum bacteremia in southern Sweden. Actinotignum
isolates in blood cultures were identified retrospectively be-
tween 1st January 2012 and 31st March 2016 through
searches in the clinical microbiology laboratory database.
The population covered by this laboratory is approximately
1.3 million. Matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) was used for
species determination. Etests were used for minimum inhibi-
tory concentration (MIC) determination. The patients’ medi-
cal charts were reviewed. Fifty-eight episodes in fifty-seven
patients with Actinotignum bacteremia were identified
(A. schaalii = 53, A. sanguinis = 1, A. urinale = 2, and
Actinotignum species = 3), which corresponds to an incidence
of 11 cases per million inhabitants. Fifty-one percent of the
isolates were in pure culture. TheMICs were low for β-lactam
antibiotics, whereas high MICs were recorded for ciprofloxa-
cin and trimethoprim. Patients had a median age of 82 years,
72% were male, and a majority had underlying urological
conditions. Thirty-six of the patients were diagnosed with a
focus from the urinary tract. Thirty-one patients developed
severe sepsis and nine patients died during the hospital stay.
Our study is the largest of Actinotignum bacteremia and dem-
onstrates that it is a condition with a significant fatality that
affects elderly persons with underlying conditions. β-Lactams
represent a rational treatment option.
Introduction
The genus Actinobaculumwas first described in 1997, when it
was separated from Actinomyces [1, 2]. Several species be-
longing to Actinobaculum were reclassified in 2015 and they
were proposed to constitute a novel genus, Actinotignum [2].
This genus now comprises three species: Actinotignum
schaalii, Actinotignum sanguinis, and Actinotignum urinale
[2]. These bacteria are small facultative anaerobic Gram-
positive rods that are non-motile and catalase-negative [1].
They grow slowly and preferably under anaerobic or CO2
conditions, and are easily overgrown by other bacteria [3].
Actinotignum species are probably part of the normal urogen-
ital flora [4] and have been associated with urinary tract infec-
tions [5, 6]. They are, however, most likely under-diagnosed
in urine cultures, since most clinical microbiological laborato-
ries routinely only use aerobic growth conditions. Matrix-
assisted laser desorption/ionization time-of-flight mass spec-
trometry (MALDI-TOF MS) appears to be a useful method
for correct species determination of these bacteria [3].
Actinotignum schaalii has been associated with urinary
tract infections [6, 7] but can also cause invasive infections,
such as Fournier’s gangrene, urinary bladder necrosis, bacter-
emia, and endocarditis [8–11]. The characteristics of infec-
tions with A. schaalii have been described in two recent re-
views [5, 12]. However, only a few studies have addressed the
clinical presentation of Actinotignum bacteremia. In a study
from Denmark, 98 patients with A. schaalii bacteremia were
identified between 2011 and 2014, but the clinical presenta-
tion was only described for ten patients [8]. These had a me-
dian age of 79 years, 70% were male, and 50% had predis-
posing urogenital conditions. In a Swedish study, 17 cases of
A. schaalii bacteremia were identified retrospectively and pa-
tients were shown to typically be older males with underlying
urogenital risk factors [13]. Similar results have been
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indicated in a case series from Spain [14], as well as in reports
of single cases and smaller case-series [7, 15–20]. Given the
low number of cases reported, the prognosis of Actinotignum
bacteremia is not known.
In published cases, the preferred treatment of A. schaalii
bacteremia has been with β-lactams to which the bacterium
has low minimum inhibitory concentration (MIC) values.
However, since bacteremia typically has a urinary tract focus,
there is a risk that empiric treatment will be given with anti-
biotics such as trimethoprim–sulfamethoxazole or ciprofloxa-
cin, to which the bacterium is resistant in vitro [16, 19, 21].
The duration of the treatment is still uncertain but there have
been failures after 1 week of ampicillin treatment [6, 19],
which indicates that longer treatment periods may be needed.
In this retrospective study, we present the incidence, clinical




Patients with any Actinotignum species in blood cultures be-
tween 1st January 2012 and 31st March 2016 were identified
through searches in the database belonging to the clinical mi-
crobiology laboratories in Malmö and Lund, Sweden. This
database contains clinical samples from all ten hospitals with-
in Region Skåne, with 1,303,627 inhabitants in 2015 [22]. The
laboratories used blood culture systems and MALDI-TOF
MS, as previously described [23]. We performed species de-
termination with 16S rRNA gene sequencing with fD1 mod
and P911 primers, as previously described [24], on all isolates
where both the initial and renewed MALDI-TOFMS analysis
gave a score below 2.0.
Clinical presentation
The medical charts were studied and the following variables
were extracted: age, underlying diseases, urogenital risk fac-
tors, symptoms, vital signs, laboratory values, antibiotic treat-
ment, diagnosis, outcome, and other microbiological findings.
Urogenital risk factors were defined as one or more of cathe-
terization, prostatic hyperplasia, prostatic cancer, bladder can-
cer, hydronephrosis, renal failure, urethral stricture, or kidney
stones. Severe sepsis was defined as one or more of hypoten-
sion with a systolic blood pressure below 90 mmHg, hypo-
perfusion with plasma lactate of >3.3 mM, or organ dysfunc-
tion. Organ dysfunction, in turn, was defined as an increase in
plasma creatinine by >44 μmol/l, saturation <86% at admis-
sion (<78% if the focus of infection was the lungs), platelets
<100 × 109/l or PK/INR >1.5, an acute confusion and/or
bilirubin >45 μmol/l [25]. A need for ventilation support,
inotropic support, or continuous hemofiltration was also
regarded as proof of organ dysfunction.
Antibiotic susceptibility
Isolates were cultured for 48 h under anaerobic conditions
(Whitley A35 Anaerobic Workstation) on blood agar plates
[produced by the Clinical Microbiology Laboratory, Lund,
Sweden, using Blood Agar Base LAB028 (LabM,
Lancashire, UK), with the addition of 5% horse blood]. The
MIC was determined using the Etest (bioMérieux, Marcy-
l’Etoile, France) on Mueller–Hinton fastidious agar plates ac-
cording to the instructions give by the manufacturer. The MIC
was recorded after 24 or 48 h of incubation anaerobically.
Statistical methods
Continuous variables were compared using the Mann–
Whitney U-test and categorical variables using the Fisher’s
exact test in Prism 7 for Mac OS X.
Results
Microbiology
A total of 58 episodes of Actinotignum bacteremia were iden-
tified, corresponding to an incidence of 11 cases per million
inhabitants per year. Fourteen of the isolates had an MALDI-
TOFMS score below 2.0 and were subjected to sequencing of
the 16S rRNA gene for species determination. Eleven isolates
were identified as A. schaalii, whereas three of the isolates
could not be securely identified to the species level and were,
thus, designated as Actinotignum species. Actinotignum
schaalii was isolated from 53 patients, A. sanguinis was iso-
lated from one patient, and A. urinale was isolated from two
patients (once with A. schaalii and once with Peptoniphilus
harei). One patient had a recurrent A. schaalii infection, with
six months between the episodes, and only the first episode is
reported here. In total, Actinotignum was the only finding in
blood in 29 cases. In the other cases, additional bacterial spe-
cies were isolated from the blood. The most common findings
were Aerococcus species (n = 9), Peptoniphilus species
(n = 4), Escherichia coli (n = 3), Enterococcus faecalis
(n = 3), and Proteus mirabilis (n = 3). In four samples, more
than two bacterial species of bacteria were isolated. The most
common bacteria found in urine were E. coli (n = 14),
E. faecalis (n = 5), and Aerococcus species (n = 3). Only one
urine sample grew A. schaalii.
Of the 54 isolates available for antimicrobial susceptibility
testing, all showed low MIC values to β-lactams and vanco-
mycin, whereas the MIC values varied for erythromycin,
clindamycin, and gentamicin. High MICs were recorded for
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trimethoprim and ciprofloxacin. The results are summarized
in Table 1. European Committee on Antimicrobial
Susceptibility Testing (EUCAST) breakpoints for Gram-
positive anaerobes were used for classification of sensitivity
[26].
Clinical presentation
The median age of the patients was 82 years and 72% were
men. Only one of the patients had no underlying conditions. A
majority of the patients (61%) had one or more underlying
urogenital conditions, the most common being prostatic dis-
orders (n = 16) and urinary catheter (n = 14). The patient char-
acteristics are summarized in Table 2. The most common
symptom at presentation was fever (61%). Nine of the patients
presented with symptoms from the urinary tract, such as he-
maturia or strong smelling urine, and nine presented with un-
specified abdominal pains. In eight subjects, the positive
blood culture was drawn after more than 48 h of hospitaliza-
tion and, thus, represent nosocomial infections.
Course and outcome
Thirty-one patients developed severe sepsis, and in 39% of
these cases, more than one organ failure was recorded.
Thirteen of the patients with severe sepsis had Actinotignum
as the single organism isolated from blood, whereas 18 of
these patients had polymicrobial bacteremia. Renal failure
was the most common organ failure (n = 17), followed by
hypoperfusion (n = 10) and respiratory failure (n = 8). Five
patients were treated in the intensive care unit with non-
invasive ventilation or vasopressor support. Thirty-six patients
were diagnosed with a focus in the urinary tract and 11 with
pneumonia, though chest radiograms were not conclusive for
pneumonia in any of these cases. Eight patients were subject-
ed to echocardiography, which did not reveal signs of
endocarditis. Fifty-three patients received adequate antibiotic
treatment initially, of which 43 were treated with β-lactams.
The most common follow-up treatment was per oral amoxi-
cillin (n = 19). A few patients received ciprofloxacin as fol-
low-up. The median time of the total antibiotic treatment was
14 days. The median time of hospitalization was 10 days for
survivors. Nine of the patients died during hospitalization. The
features of deceased patients and survivors are given in Table 3.
Discussion
The number of reported cases ofActinobaculum/Actinotignum
bacteremia has been very low, possibly due to the relatively
recent identification of the species and missed identification in
the microbiological laboratories. With MALDI-TOF MS as
the primary species identification method and an increasing
number of older persons with urinary tract morbidity,
Actinotignum infections will likely be more frequently en-
countered.We report an incidence ofActinotignum bacteremia
of 11 cases per million inhabitants per year, which is higher
than what is suggested by a recent Danish study [8]. Our
results confirm previous studies showing that patients affected
by the condition are typically older males with underlying
urinary tract conditions [8, 13, 14]. From our case series,
which is the largest one to date, the prognosis of
Actinotignum bacteremia can be assessed. We report a rela-
tively high mortality (16%), which is likely related to the
advanced age and co-morbidity of the patients. Some of the
deceased patients had polymicrobial bacteremia and the exact
contribution of A. schaalii to the outcome is difficult to
determine.
Actinotignum schaalii is the most commonly isolated
Actinotignum species both in our study and in previous reports
[6–8, 13]. We identified one case of A. sanguinis and two
cases of A. urinale bacteremia. However, MALDI-TOF MS
Table 1 Minimum inhibitory concentration (MIC) values for the 54 Actinotignum isolates
Antibiotics MIC values
0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 128 >256
Bensylpenicillin 2 9 26 14 3
Ampicillin 4 2 2 6 15 16 5 4
Cefotaxime 12 15 16 4 6 1
Imipenem 1 3 16 23 10 1
Vancomycin 1 19 31 2 1
Gentamicin 2 15 32 1 3 1
Ciprofloxacin 1 1 4 4 3 3 38
Trimethoprim 54
Clindamycin 19 16 10 1 1 1 6
Erythromycin 20 17 10 1 6
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was unable to reliably identify all isolates to the species level.
Sequencing of the 16S rRNA gene proved to have a limited
ability to separate A. schaalii from A. sanguinis and, therefore,
some isolates could not be identified to the species level.
There are many similarities between A. schaalii and
Aerococcus urinae [27]. Both species probably colonize the
urinary tract and they have been difficult to correctly identify
in the past. They cause invasive infections mostly in older
males with underlying urogenital conditions, and are resistant
to antibiotics commonly used to treat urinary infections. In
fact, Actinotignum species and Aerococcus species have been
isolated together from blood previously [18, 23] and, in our
material, Aerococcus was the most common finding in
polymicrobial Actinotignum bacteremia. Our previous de-
scription of Aerococcus bacteremia and the present descrip-
tion of Actinotignum bacteremia, however show some differ-
ences [23, 28, 29]. The mortality is higher in Actinotignum
bacteremia as compared to Aerococcus bacteremia (16 vs.
8%) [18, 23]. This could either be due to specific bacterial
virulence factors expressed by Actinotignum or also be due
to host factors such as more advanced underlying conditions.
Another difference is that Actinotignum species rarely seem to
cause infective endocarditis as opposed to Aerococcus spe-
cies, which cause endocarditis in a significant proportion of
cases of bacteremia [23, 30, 31]. In our series, no case of
endocarditis was found and only a single case of endocarditis
caused by Actinotignum has been reported previously [9].
Only in one of the patients was A. schaalii isolated from
urine. This is most likely due to routine practices in the clinical
microbiology laboratory, which are unfavorable for the detec-
tion of Actinotignum species. Our findings, however, suggest
that the urinary tract was the focus of the bacteremia in a
majority of the cases.Many patients had underlying urological
conditions and presented with signs and symptoms from the
urinary tract. The patients with polymicrobial bacteremia had
other typical uropathogens in their blood and urine cultures,
such as Aerococcus species, E. coli, and E. faecalis, which
also suggest a urinary tract focus. The patients who received
a clinical diagnosis of pneumonia did not fulfill criteria nec-
essary for that diagnosis and most of them likely had a urinary
tract focus of infection.
There are no clinical break points established for
Actinotignum species. However, from our results on antimi-
crobial susceptibility testing,β-lactams and vancomycin seem
like feasible treatment options. Trimethoprim and ciprofloxa-
cin display high MIC values and should be avoided. Previous
studies have reported relapse of A. schaalii infections, which
Table 2 Clinical features of Actinotignum bacteremia
Demographics
Median age (years) 82 (range 48–98)
Male sex 41 (72%)
Microbiology
Pure culture 29 (51%)
Positive urine cultures 26 (46%)
Underlying conditions
Urogenital conditionsa 35 (61%)
Cardiovascular diseaseb 39 (68%)
Dementia 8 (14%)
Diabetes mellitus 11 (19%)
Symptoms and signs
Fever 35 (61%)
Urinary tract symptoms 9 (16%)
Respiratory symptoms 17 (30%)
Severe sepsis 31 (54%)
Median CRPc at hospitalization 59 mg/L (range 2–420)
Median WBCd at hospitalization 14 × 109/L (range
5.8–50)
Focus of infection




Initial antibiotic effective against
Actinotignum
53 (93%)
Median in-hospital time (days) 10 (range 2–25)
Echocardiogram 8 (14%)
ICUe 5 (9%)
Deceased during hospitalization 9 (16%)
aUnderlying conditions defined as one or more of catheterization, pros-
tatic hyperplasia, prostatic cancer, bladder cancer, hydronephrosis, renal
failure, urethral stricture, lower urinary tract symptoms (LUTS), or kid-
ney stones
b Underlying conditions defined as atrial fibrillation, pacemaker, ischemic
heart disease, myocardial infarction, or stroke
c C-reactive protein
dWhite blood cells
e Intensive care unit
Table 3 Features of survivors and the deceased
Survivors Deceased p-
Value
Median age 81 years 86 years 0.03
Male sex 33/48 (69%) 8/9 (89%) 0.4
Pure culture 26/48 (54%) 2/9 (22%) 0.1
Severe sepsis 22/48 (46%) 9/9 (100%) 0.003
Median CRPa at hospitalization 58 59 0.3
Median WBCb at hospitalization 13 16 0.3
Underlying urogenital conditions 29/48 (60%) 5/9 (56%) 1
Urinary tract focus of infection 32/48 (67%) 3/9 (33%) 0.1
Nosocomial infection 5/48 (10%) 2/9 (22%) 0.3
Adequate initial antibiotic treatment 44/48 9/9 1
a C-reactive protein
bWhite blood cells
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has led to suggestions of prolonged treatment [6, 19]. The
median length of antibiotic treatment in this serieswas 2weeks
and, to our knowledge, there were no treatment failures. One
patient had two episodes of A. schaalii bacteremia during a 6-
month period, and this represented a recurrent infection rather
than a treatment failure.
In conclusion, our results demonstrate that Actinotignum
bacteremia is more common than previously thought and that
it represents a condition with a significant fatality in elderly
patients with underlying conditions. The urinary tract should
be suspected as the primary focus of infection but, unfortu-
nately, Actinotignum species seldom grow in ordinary urine
culture conditions.
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